Positiv
●
Forbes
●
vor 4 Monaten
Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging Phase 1 results. This information, combined with an impressive revenue exceedance, is fostering considerable optimistic sentiment.